S&P 500
(1.02%) 5 099.96 points
Dow Jones
(0.40%) 38 240 points
Nasdaq
(2.03%) 15 928 points
Oil
(0.11%) $83.66
Gas
(-3.32%) $1.920
Gold
(0.30%) $2 349.60
Silver
(-0.43%) $27.52
Platinum
(0.42%) $924.40
USD/EUR
(0.32%) $0.935
USD/NOK
(0.67%) $11.02
USD/GBP
(0.13%) $0.800
USD/RUB
(-0.07%) $92.11

Echtzeitaktualisierungen für Enzo Biochem Inc [ENZ]

Börse: NYSE Sektor: Healthcare Industrie: Diagnostics & Research
Zuletzt aktualisiert26 Apr 2024 @ 22:00

-1.87% $ 1.050

Live Chart Being Loaded With Signals

Commentary (26 Apr 2024 @ 22:00):

Enzo Biochem, Inc., an integrated diagnostics, clinical lab, and life sciences company, researches, develops, manufactures, and markets diagnostic and research products based on genetic engineering, biotechnology, and molecular biology...

Stats
Tagesvolumen 114 913
Durchschnittsvolumen 109 219
Marktkapitalisierung 53.79M
EPS $0 ( 2024-03-19 )
Nächstes Ertragsdatum ( $0 ) 2024-06-12
Last Dividend $0.0470 ( 1995-06-29 )
Next Dividend $0 ( N/A )
P/E -2.23
ATR14 $0.00300 (0.29%)
Insider Trading
Date Person Action Amount type
2024-02-23 Cannon Kara Buy 150 000 Common Stock
2024-02-21 Cannon Kara Buy 10 640 Common Stock
2024-02-21 Cannon Kara Sell 5 823 Common Stock
2024-02-23 Eckert Patricia Buy 75 000 Stock Option (to acquire shares of Common Stock)
2024-01-31 Pully Steven J Buy 79 365 Common Stock
INSIDER POWER
88.53
Last 85 transactions
Buy: 4 325 861 | Sell: 177 248

Volumen Korrelation

Lang: 0.27 (neutral)
Kurz: -0.56 (weak negative)
Signal:(51.331) Neutral

Enzo Biochem Inc Korrelation

10 Am meisten positiv korreliert
YSAC0.906
TSQ0.849
HZN0.841
DTC0.828
CRD-A0.819
10 Am meisten negativ korreliert
FPEI-0.872
ASB-PE-0.868
CUBB-0.868
GL-0.855
FLR-0.852
NX-0.843
MBI-0.836
PQDI-0.832
BGSF-0.832
SPNT-PB-0.825

Wussten Sie das?

Korrelation ist ein statistisches Maß, das die Beziehung zwischen zwei Variablen beschreibt. Es reicht von -1 bis 1, wobei -1 eine perfekte negative Korrelation (wenn eine Variable zunimmt, nimmt die andere ab) anzeigt, 1 eine perfekte positive Korrelation (wenn eine Variable zunimmt, nimmt die andere zu) und 0 keine Korrelation anzeigt (es besteht kein Zusammenhang zwischen den Variablen).

Korrelation kann verwendet werden, um die Beziehung zwischen beliebigen zwei Variablen zu analysieren, nicht nur zwischen Aktien. Es wird häufig in Bereichen wie Finanzen, Wirtschaft, Psychologie und mehr verwendet.

Enzo Biochem Inc Korrelation - Währung/Rohstoff

The country flag 0.00
( neutral )
The country flag 0.51
( weak )
The country flag 0.00
( neutral )
The country flag 0.00
( neutral )
The country flag 0.00
( neutral )
The country flag 0.16
( neutral )

Enzo Biochem Inc Finanzdaten

Annual 2023
Umsatz: $31.06M
Bruttogewinn: $11.57M (37.24 %)
EPS: $-1.270
FY 2023
Umsatz: $31.06M
Bruttogewinn: $11.57M (37.24 %)
EPS: $-1.270
FY 2022
Umsatz: $107.07M
Bruttogewinn: $41.97M (39.20 %)
EPS: $-0.460
FY 2021
Umsatz: $117.73M
Bruttogewinn: $53.58M (45.51 %)
EPS: $0.160

Financial Reports:

No articles found.

Enzo Biochem Inc Dividends

(Q3/22) (Q4/22) (Q1/23) (Q2/23) (Q3/23) (Q4/23) (Q1/24) (Q2/24) (Q3/24) (Q4/24)
$0
(N/A)
$0
(N/A)
$0
(N/A)
$0
(N/A)
$0
(N/A)
$0
(N/A)
$0
(N/A)
$0
(N/A)
$0
(N/A)
$0
(N/A)

Enzo Biochem Inc Dividend Information - No Dividend Player

Dividend Sustainability Score: 5.02 - average (34.50%) | Divividend Growth Potential Score: 0.366 - No dividend growth expected in the near future
Information
First Dividend $0.0470 1995-06-29
Last Dividend $0.0470 1995-06-29
Next Dividend $0 N/A
Payout Date 0000-00-00
Next Payout Date N/A
# dividends 1 --
Total Paid Out $0.0470 --
Avg. Dividend % Per Year 0.00% --
Score 0.82 --
Div. Sustainability Score 5.02
Div.Growth Potential Score 0.366
Div. Directional Score 2.69 --
Next Divdend (Est)
(2024-04-28)
$0 Estimate 0.00 %
Dividend Stability
0.00 Very Bad
Dividend Score
0.82
Pay Frequency
Insufficient data to determine frequency
Yearly Payout
Year Amount Yield
1995 $0.0470 0.58%
1996 $0 0.00%
1997 $0 0.00%
1998 $0 0.00%
1999 $0 0.00%
2000 $0 0.00%
2001 $0 0.00%
2002 $0 0.00%
2003 $0 0.00%
2004 $0 0.00%
2005 $0 0.00%
2006 $0 0.00%
2007 $0 0.00%
2008 $0 0.00%
2009 $0 0.00%
2010 $0 0.00%
2011 $0 0.00%
2012 $0 0.00%
2013 $0 0.00%
2014 $0 0.00%
2015 $0 0.00%
2016 $0 0.00%
2017 $0 0.00%
2018 $0 0.00%
2019 $0 0.00%
2020 $0 0.00%
2021 $0 0.00%
2022 $0 0.00%
2023 $0 0.00%
2024 $0 0.00%

Dividend Commentary

With a moderate Dividend Sustainability Score (DSS), the company may sustain its dividends, but continuous monitoring is advised for any financial shifts. Unfortunately, its low Dividend Growth Potential Score (DGPS) suggests limited prospects for dividend growth. In conclusion, a more vigilant stance is recommended given the company's tentative dividend landscape.

Top 10 dividend Companies for NYSE

Symbol Title Last dividend Frequency Years Dividend Yearly Dividend Score
LOMA Dividend Knight 2023-06-30 Quarterly 2 5.23% 8.53
VGI Dividend Royal 2024-02-09 Monthly 13 7.36% 8.50
JQC Dividend Royal 2023-11-14 Monthly 22 6.56% 8.50
PHK Dividend Royal 2023-11-10 Monthly 22 6.88% 8.50
PCF Dividend King 2023-12-18 Monthly 38 7.05% 8.50
PVL Dividend King 2023-11-15 Monthly 14 9.37% 8.50
NCV Dividend Royal 2024-02-09 Monthly 22 7.68% 8.50
SBR Dividend Royal 2023-11-14 Monthly 38 7.74% 8.50
MTR Dividend Diamond 2023-10-30 Monthly 39 10.10% 8.50
PDI Dividend Royal 2023-11-10 Monthly 13 7.86% 8.50

Dividend Sustainability Score (DSS)

RatioActual ValueWeightNormalized ValueScoreRange
netProfitMarginTTM2.581.50010.0010.00[0 - 0.5]
returnOnAssetsTTM0.3331.20010.0010.00[0 - 0.3]
returnOnEquityTTM0.5451.5005.067.59[0.1 - 1]
payoutRatioTTM0-1.00000[0 - 1]
currentRatioTTM3.200.80010.008.00[1 - 3]
quickRatioTTM2.780.80010.008.00[0.8 - 2.5]
cashRatioTTM2.581.50010.0010.00[0.2 - 2]
debtRatioTTM0.0444-1.5009.26-10.00[0 - 0.6]
interestCoverageTTM33.771.00010.0010.00[3 - 30]
operatingCashFlowPerShareTTM-0.8792.00-0.293-0.586[0 - 30]
freeCashFlowPerShareTTM-0.9092.00-0.455-0.909[0 - 20]
debtEquityRatioTTM0.0621-1.5009.75-10.00[0 - 2.5]
grossProfitMarginTTM-1.2031.000-10.00-10.00[0.2 - 0.8]
operatingProfitMarginTTM-0.3481.000-8.96-8.96[0.1 - 0.6]
cashFlowToDebtRatioTTM-10.101.000-10.00-10.00[0.2 - 2]
assetTurnoverTTM0.1290.800-2.47-1.977[0.5 - 2]
Total Score5.02

Dividend Growth Score (DGS)

RatioActual ValueWeightNormalized ValueScoreRange
peRatioTTM1.6051.0009.940[1 - 100]
returnOnEquityTTM0.5452.506.827.59[0.1 - 1.5]
freeCashFlowPerShareTTM-0.9092.00-0.303-0.909[0 - 30]
dividendYielPercentageTTM01.50000[0 - 0.4]
operatingCashFlowPerShareTTM-0.8792.00-0.293-0.586[0 - 30]
payoutRatioTTM01.50000[0 - 1]
pegRatioTTM-0.009121.500-3.390[0.5 - 2]
operatingCashFlowSalesRatioTTM-3.471.000-10.000[0.1 - 0.5]
Total Score0.366

Enzo Biochem Inc

Enzo Biochem, Inc., an integrated diagnostics, clinical lab, and life sciences company, researches, develops, manufactures, and markets diagnostic and research products based on genetic engineering, biotechnology, and molecular biology. It operates through three segments: Life Sciences Products, Clinical Laboratory Services, and Therapeutics. The Life Sciences Products segment develops, manufactures, and markets products and tools to clinical research, drug development, and bioscience research customers. It offers proteins, antibodies, peptides, small molecules, labeling probes, dyes, and kits, which provide life science researchers tools for target identification/validation, content analysis, gene expression analysis, nucleic acid detection, protein biochemistry and detection, and cellular analysis. This segment also provides its products to scientific experts in the fields of cancer, cardiovascular disease, neurological disorders, diabetes and obesity, endocrine disorders, infectious and autoimmune disease, hepatotoxicity, and renal injury. The Clinical Laboratory Services segment provides molecular and other clinical laboratory tests or procedures used in general patient care by physicians to establish or support a diagnosis, monitor treatment or medication, and search for an otherwise undiagnosed condition. It operates a full-service clinical laboratory in Farmingdale, New York; a network of 30 patient service centers in New York and New Jersey; and a free-standing ‘STAT' or rapid response laboratories in New York City and Connecticut, as well as a full-service phlebotomy center and an in-house logistics department. The Therapeutics segment develops novel approaches in the areas of gastrointestinal, infectious, ophthalmic, and metabolic diseases. It markets its products and services through its direct sales force and a network of distributors in the United States and internationally. The company was founded in 1976 and is headquartered in New York, New York.

Über Live-Signale

Die Live-Signale auf dieser Seite helfen dabei zu bestimmen, wann man NA kaufen oder verkaufen soll. Die Signale haben eine Verzögerung von bis zu 1 Minute; wie bei allen Marktsignalen besteht die Möglichkeit von Fehlern oder Fehleinschätzungen.

Die Live-Handelssignale sind nicht endgültig und getagraph.com übernimmt keine Verantwortung für Maßnahmen, die aufgrund dieser Signale ergriffen werden, wie in den Nutzungsbedingungen beschrieben. Die Signale basieren auf einer breiten Palette von technischen Analyseindikatoren.